Total trials
139
Active
2
Phase 3
36
Total enrollment
22,863
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| CYB704 | — | — | — | — | — | 1 | |
| Ocrevus-EU | — | — | — | — | — | 1 | |
| Ocrevus-US | — | — | — | — | — | 1 |
Next readouts
- 2026-11
Top conditions
- Depression13
- Healthy11
- HIV Infections10
- Hypertension8
- Cytopenias6
- Rheumatoid Arthritis6
- Anemia5
- Inflammation4
Frequently asked questions about Sandoz
- How many clinical trials does Sandoz have on ClinicalTrials.gov?
- Sandoz is listed as the lead sponsor on 139 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sandoz's trials are in Phase 3?
- 36 of Sandoz's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Sandoz focus on?
- Sandoz's most-studied conditions on ClinicalTrials.gov are Depression, Healthy, HIV Infections, Hypertension, Cytopenias.
- When are Sandoz's next clinical trial readouts?
- Sandoz has 1 upcoming primary-completion readout tracked here; the soonest is “Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis”, expected around 2026-11.